so all you have to do is sit back and relax. The Shine & Protect Glass action ensures your glassware maintains a sparkling shine for longer, and the Silver Protection provides added protection for your silverware. Finish Quantum tablets are safe for septic sy...
Safe for septic systems Safe for washing machines 5 simple steps to lasting odor relief Add directly to urine in all portable urine containers Use 1 tablet for every 16 fluid oz. of urine & add more as needed Tablets will dissolve slowly over 4-6 hours to increase time-release effects ...
USE: Place a tab in pool skimmer, floater, or feeder for simple, DIY pool care; 1 tablet treats 10,000 gallons of water for up to a week COMPATIBILITY: Vinyl-lined pools and saltwater systems FEATURES: Kills bacteria and algae; Chlorinates for up to 1 week; Clarifies water; Sun pro...
Convenient rust stain solution; Long-lasting formula prevents rust stains from forming in toilet bowl for up to 45 days Safe for use with all toilets, internal toilet components, plumbing and septic systems Simply drop tablet in toilet tank and let Iron OUT do the...
Fertility studies in animals have not been conducted with quizartinib. However, adverse findings in male and female reproductive systems were observed in repeat-dose toxicity studies in rats and monkeys. Findings in female animals (rats or monkeys) included ovariancysts, vaginal mucosal modifications, ...
Transporter Systems Elacestrant is a substrate for OATP2B1, but not P-gp. Elacestrant is not an inhibitor of OAT1, OAT3, OCT2, MATE1, MATE2-K, OCT1, OATP1B1, OATP1B3 or OATP2B1. Clinical Studies The efficacy of ORSERDU was evaluated in EMERALD (NCT03778931), a randomized, op...
Transporter Systems Revumenib is a substrate of OCT1, OCT2, OAT1, OAT3, and MATE1, but is not a substrate of P-gp, BCRP, OATP1B1, OATP1B3, MATE2-K, or BSEP. M1 is a substrate of OATP1B1, but is not a substrate of P-gp, BCRP, OCT2, OAT1, OAT3, OATP1B3, MATE1, or...
Enzymes Systems Belumosudil is an inhibitor of CYP1A2, CYP2C19, CYP2D6, UGT1A1 and UGT1A9. Clinical Studies Chronic Graft Versus Host Disease Study KD025-213 (NCT03640481) was a randomized, open-label, multicenter study of REZUROCK for treatment of patients with chronic GVHD who had recei...